Q-omics provides the consensus-scored SUMO2P19 profile across patient tissues and cancer cell-line models. SUMO2P19 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SUMO2P19 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, SUMO2P19 RNA expression shows 17,653 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where SUMO2P19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUMO2P19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUMO2P19 survival associations across molecular data types. SUMO2P19 RNA expression shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUMO2P19 RNA expression–survival associations across cancer types. High SUMO2P19 expression shows unfavorable associations in KIRC, KICH, UVM and LUSC, but favorable associations in BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SUMO2P19 RNA expression.
This table summarizes SUMO2P19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SUMO2P19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUMO2P19 shows lower tumor expression in THCA and higher tumor expression in HNSC, CHOL, STAD, COAD and LIHC. The THCA box plot shows higher SUMO2P19 RNA expression in normal versus tumor tissue (log2 FC = −0.466, t-test p < 0.001).
This table shows molecular features associated with SUMO2P19 in patient tissues and cancer cell lines. In patient samples, SUMO2P19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
